neuroClues® raises €10M Series A to expand AI neurological biomarkers across Europe and enter the U.S.

neuroClues announces a €10 million Series A to accelerate one of the fastest clinical rollouts in European neurotech, while concurrently securing additional non-dilutive funding, bringing the total capital raised by neuroClues to €25 million.

The round is led by Teampact Ventures, White Fund and the EIC Fund (European Innovation Council), with participation from existing investors (InvestBW, Leansquare, Wallonie Entreprendre) and the support of Olivier Legrain, Chairman of the Board and CEO of IBA.

Neurodegenerative diseases are increasingly prevalent, affecting 1 in 3 people while remaining difficult to diagnose. The number of people affected by Parkinson’s disease worldwide is expected to double to 13 million by 2040. Yet one in five patients is still misdiagnosed and by the time the disease is correctly identified, irreversible brain damage has already occurred leading to a loss of 65% of affected neurons. The reasons: clinicians still rely mostly on clinical observations with no quantitative output such as the “follow my finger” test, and advanced technologies (e.g. imaging) are costly, not widely accessible and often fail to detect abnormalities at early disease stages.

This detection gap impacts quality of life, wastes healthcare resources, and delays treatments.

neuroClues has built a portable, CE-marked class IIa medical device that extracts neurological biomarkers from eye movements in minutes. A compact device captures high-speed infrared images of each eye while the patient performs simple visual tasks. Proprietary AI algorithms then compute objective, reproducible biomarkers, turning a century of oculomotor research into a practical clinical tool.

Its constraint-free, plug and play design with immediate integration in the clinical workflow bring results in minutes (remote interpretation possible) providing critical clues within the consultation time, not months after.

Today, neuroClues supports clinicians in assessing neurological anomalies objectively, replacing the subjective “follow my finger” test with quantified, reproducible data. Tomorrow, as the platform accumulates clinical data at scale, it aims at supporting the identification of specific pathologies: distinguishing Parkinson’s from atypical parkinsonisms, flagging early signs of Alzheimer’s, detecting concussion-related impairments. Each device deployed makes the platform smarter.

Commercial traction: from CE mark to 7 countries in months

neuroClues obtained its CE certification in January 2025. Within months, over 30 devices were deployed across France, Belgium, Italy, Germany, Switzerland, the Netherlands and the United Kingdom, in university hospitals, private neurology practices and research centers. The company reports growing inbound demand from clinicians who have seen the device at congresses or referenced by peers.

This commercial momentum is backed by landmark clinical partnerships:

• Integration into the Paris Brain Institute’s (ICM) clinical cohorts, including the Iceberg study on Parkinson’s disease
• Selection for the mega-cohort (25,000 participants), which will build the first large-scale normative database of oculomotor biomarkers
• Selected by Bpifrance’s National Prevention Accelerator, accelerating the commercialization through dedicated support.
• Member of an official French presidential delegation to India, unlocking strategic partnerships with leading institutions such as AIIMS.

To match this demand, neuroClues has appointed Bart Stulens, former VP Neuromodulation EMEA at Medtronic, as Chief Commercial Officer. The company is actively scaling its commercial team across Europe, with hires underway in France and distributor agreements signed or under discussions in the EMEA region.

neuroClues has chosen to open a limited tranche up to €1.5M on LITA, the European impact investment platform, allowing citizens and individual investors to participate directly in this round, on the same terms as institutional investors.

Photo credit: neuroClues